Zurich Cantonal Bank
FDMT icon

Zurich Cantonal Bank’s 4D Molecular Therapeutics FDMT Stock Holding History

Zurich Cantonal Bank’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13 Hold
1
– – ﹤0.01% 2544
2026
Q1 		$9 Hold
1
– – ﹤0.01% 2539
2025
Q4 		$8 Hold
1
– – ﹤0.01% 2533
2025
Q3 		$9 Hold
1
– – ﹤0.01% 2547
2025
Q2 		$4 Hold
1
– – ﹤0.01% 2558
2025
Q1 		$3 Sell
1
-5,557
-100% -$26.2K ﹤0.01% 2624
2024
Q4 		$31K Sell
5,558
-154
-3% -$1.21K ﹤0.01% 2580
2024
Q3 		$61.7K Hold
5,712
– – ﹤0.01% 2530
2024
Q2 		$120K Sell
5,712
-18
-0.3% -$452 ﹤0.01% 2304
2024
Q1 		$183K Buy
5,730
+159
+3% +$4.06K ﹤0.01% 2099
2023
Q4 		$113K Sell
5,571
-1,195
-18% -$15.7K ﹤0.01% 2388
2023
Q3 		$86.1K Sell
6,766
-222
-3% -$3.71K ﹤0.01% 2419
2023
Q2 		$126K Buy
6,988
+5,910
+548% +$109K ﹤0.01% 2219
2023
Q1 		$18.5K Buy
+1,078
New +$21K ﹤0.01% 2768
2022
Q4 		– Sell
-2,114
Closed -$17K – 2865
2022
Q3 		$17K Hold
2,114
– – ﹤0.01% 2822
2022
Q2 		$15K Hold
2,114
– – ﹤0.01% 2823
2022
Q1 		$32K Hold
2,114
– – ﹤0.01% 2601
2021
Q4 		$46K Buy
+2,114
New +$51.8K ﹤0.01% 2767

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Zurich Cantonal Bank's FDMT Position: Q2 2026 in Review

Zurich Cantonal Bank held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 1 share worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #2544.

Zurich Cantonal Bank first reported a position in FDMT in Q4 2021 and has held it in 18 quarters since. The position peaked at $183K in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Zurich Cantonal Bank held 1 share of 4D Molecular Therapeutics worth $13 as of Q2 2026.
  • Zurich Cantonal Bank left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2544 holding.
  • Zurich Cantonal Bank first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Zurich Cantonal Bank's 4D Molecular Therapeutics position peaked at $183K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.